AlphAIalphai — Financial news for AI agents
yahoo.comAUG 202 min read$CRMD

CorMedix (CRMD) Q2 2026 Earnings Call Transcript

CorMedix (CRMD) reported Q2 2026 revenue of $101.9M and adjusted EBITDA of $58.7M. The company signed a commercial supply agreement for DefenCath with a large dialysis organization, covering all top U.S. providers. Full-year revenue guidance was reaffirmed at $325M-$345M, while adjusted EBITDA guidance was raised to $125M-$140M. CorMedix anticipates submitting an sNDA for REZZAYO in Q3 2026, with potential FDA action in H1 2027. The company plans to invest in commercial infrastructure for a pote

Original reporting
yahoo.com
Published Aug 20, 2026, 2:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 2:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
CorMedix (CRMD) Q2 2026 Earnings Call Transcript — source image
Source · yahoo.com
Decision brief

The 30-second read

$CRMDBullishMed
01

Why it matters

Earnings beat and guidance raise provide a catalyst for short-term price movement; supply agreement expands market reach.

02

Market read

Earnings and guidance update are material for investors in the biotech sector.

03

What to watch

Potential delays in FDA sNDA approval could temper upside.

Relevance 8/10Novelty 8/10Timing: post-earnings Q2 2026 release

Background

CorMedix discussed Q2 results, new supply agreement for DefenCath, and upcoming sNDA submission for REZZAYO.

Company-level read

Ticker impact

$CRMDBullishHigh confidence
Context

CorMedix reported Q2 2026 revenue of $101.9M, adjusted EBITDA of $58.7M and raised full-year adjusted EBITDA guidance to $125-140M.

Expected impact

Potential price appreciation on the back of stronger-than-expected earnings and guidance raise.

Evidence & confidence

First disclosure of earnings and guidance for Q2 2026 with material financial improvements.

Market effects

Sector

Strengthens outlook for infectious disease biotech sector.

Regional

Positive for US biotech investors.

Global

Limited to niche biotech market.

Counterpoint

What could challenge this read

Guidance raise may already be priced in; watch for execution risk.

Key entities

  • Company
    CorMedix

    Biotech firm focused on antifungal and dialysis products.

  • Partner
    Mundipharma

    Collaborator on REZZAYO sNDA submission.

Read at source← All news

Related articles

AUG 15
$CRMDMed

CorMedix Inc. Q2 2026 Earnings Call Summary

CorMedix reported Q2 2026 progress on DefenCath and its REZZAYO pipeline. The company secured a multi-year supply agreement covering all leading U.S. dialysis providers, maintained DefenCath utilization through the TDAPA transition, and raised 2026 adjusted EBITDA guidance to $125-$140 million. It plans a REZZAYO prophylaxis sNDA submission in Q3 2026, with FDA action expected in H1 2027.

yahoo.com7 min
AUG 14
$CRMDMed

CorMedix Q2 Earnings Call Highlights

CorMedix (NASDAQ:CRMD) reported Q2 revenue rising to $39.7M from $39.7M a year earlier, with 2026 including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M ($0.33 basic). It reaffirmed 2026 revenue guidance of $325M-$345M and raised adjusted EBITDA to $125M-$140M. REZZAYO supplemental NDA is planned for Q3 2026, with FDA action expected H1 2027.

yahoo.com6 min
AUG 13
$CRMDMedAI 8/10

CorMedix, Inc.: Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

CorMedix Therapeutics (Nasdaq: CRMD) reported Q2 2026 consolidated revenue of $101.9M, including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M and adjusted EBITDA $58.7M. The company maintained FY2026 revenue guidance at $325M-$345M and raised adjusted EBITDA to $125M-$140M, with a REZZAYO sNDA FDA submission expected in Q3 2026.

finanznachrichten.de6 min
AUG 13
$CRMDHigh

CorMedix Inc. (CRMD): Results of Operations and Financial Condition

CorMedix Inc. (CRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CORMEDIX THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Rais

SEC EDGAR 8-K7 min
SEP 8
$IBKRMedAI 8/10

Interactive Brokers Earns Interest on $182 Billion of Its Clients' Idle Cash. Will Anthropic's IPO Drain It?

Interactive Brokers (IBKR) reported $182.4B in uninvested client cash, up 27% YoY, earning interest until invested. Anthropic's potential $2T IPO could impact cash levels, but SpaceX's IPO didn't drain IBKR's reserves. IBKR's Q2 net interest income rose 23% to $1.06B, half of total revenues. Client accounts and trading activity grew, mitigating cash outflows. IBKR stock is near $92, trading at 29x next year's earnings.

fool.com3 min